Ranbaxy gets FDA approval to sell Furosemide tablets

By Elaine Rigoli

Tampa, Fla., Sept. 21 - Ranbaxy Laboratories, Ltd. has received approval from the Food and Drug Administration to manufacture and market Furosemide tablets USP, 20 mg, 40 mg and 80 mg.

The FDA's Office of Generic Drugs determined the Haryana, India-based pharmaceutical company's formulations to be bioequivalent and have the same therapeutic effect as that of the reference-listed drug Lasix tablets, 20 mg, 40 mg and 80 mg, respectively, of Aventis Pharmaceuticals, Inc.

Annual market sales are about $70 million, according to a news release.

Furosemide is indicated in adults, infants and children for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.